The efficacy of ranitidine (150 mg twice daily) and cimetidine (200 mg three times daily and 400 mg at night) in the short-term healing of duodenal ulcer has been assessed in a randomized controlled trial involving 106 patients. There were 3 drop-outs. Fortytwo out of 53 patients (791%) treated with ranitidine had healed ulcers at 4 weeks compared with 37 out of 50 treated with cimetidine (74%). This difference is not significant. At 8 weeks the healing rate for ranitidine (98o) was significantly greater than that for cimetidine (86%) (P<0 05). There was no significant difference in healing rates between men and women and between smokers and non-smokers. Side effects were not a problem with either drug. There were no differences of clinical significance between laboratory values in the two treatment groups, although a minor increase in mean creatinine levels occurred in the cimetidine-treated group.
Introduction
Ranitidine, the second H2 receptor antagonist to be introduced into clinical practice in the United Kingdom, has been shown to have a marked inhibitory effect on gastric acid secretion, greater than that of cimetidine. We report a trial comparing ranitidine and cimetidine in the short-term healing of duodenal ulceration.
Patients and methods
Patients with endoscopically proven duodenal ulcer have been admitted to a single-centre randomized single-blind (endoscopist) trial (1) Ulcer healing has been assessed using the twosided Mantel-Haenszel chi-square test without continuity correction (Snedecor and Cochran, 1967) .
In view of the difference in length of dyspeptic history between the two treatment groups, an analysis of the efficacy data was carried out after stratification into two groups with a relative short (under 5 years) or long (over 5 years) history.
(2) Data for selected laboratory investigations were analysed for differences between the mean or geometric mean values in the treatment groups at the pretreatment and 28-day visits. The calculation of (Satterthwaite, 1946) .
Results
Between January and November 1981, 106 patients were entered in the trial. There were 3 dropouts, 2 associated with failure of compliance, and one man who complained of a light-headed sensation which he attributed to the treatment agent. All 3 had received cimetidine. One hundred and three patients completed the trial, 53 (39 men and 14 women) received ranitidine and 50 (39 men and 11 women) received cimetidine. The background data of patients completing the trial are shown in Table 1 . The drug groups were evenly matched apart from the duration of dyspepsia which was on average 5-7 years in the ranitidine group and 13 years in the cimetidine group.
After 4 weeks, 42 (79%) patients on ranitidine and 37 (74%) on cimetidine had healed. This difference is not significant. After 8 weeks, 52 (98%) on ranitidine and 43 (86%) on cimetidine had healed. This difference is statistically significant (P<0 05). In view of the difference in the duration of the dyspeptic history between the ranitidine-and cimetidine-treated groups, healing rates were compared according to the length of history. There was no difference between groups with histories of less than or greater than 5 years (Table 2 ). In addition, there were no significant differences between smokers and non-smokers (Table 3) and between men and women, although the healing rate for men on ranitidine at 8 weeks (100%o) was significantly better than those on cimetidine (87%) (P<0 05) (Table 4) . Differences between men and women are not significant. The healing rate for men on ranitidine (100%) at 8 weeks is significantly different from the rate on cimetidine (87%) (P<005).
Unwanted effects
These were minimal. One patient declined to continue treatment with cimetidine, attributing extreme lethargy to the effects of the drug. One man, receiving cimetidine, complained of severe, central (Joffe and Lee, 1978; Szabo and Goldman, 1978) . One patient on ranitidine and one on cimetidine felt general malaise, but in both cases the condition resolved while the patients continued taking the treatment agent.
Laboratory investigations
Data for assessing changes in laboratory measurements were analysed if measurements were made at Visit 1 (pretreatment) and at Visit 3 if this was 21-35 days after Visit 1. There were no significant differences between the two groups for either visit for haemoglobin, platelet count, total white count, serum bilirubin, urea or aspartate transaminase levels and there were no significant changes between visits. In the cimetidine treatment group, the mean serum creatinine level rose from 93 to 102 mmol/litre, whereas the level remained at 92 mmol/litre in the ranitidine group. This observation has been made previously (Larsson et al., 1980) and is not thought to be clinically important. A slight fall in gamma glutamyl transaminase levels in the ranitidine group was matched by a slight rise in the cimetidine-treated groups. The difference was of statistical, but not clinical, significance.
Discussion
The present study confirms the effectiveness of ranitidine and cimetidine in the healing of duodenal ulceration. The healing rate for ranitidine was similar to that for cimetidine at 4 weeks, and at 8 weeks was significantly better (P<0-05). Some early studies are shown in Table 5 (Berstad et al., 1980; Gibinski et al., 1981; Walt et al., 1981; Dobrilla et al., 1981; . A previous report from this centre, involving 50 patients, showed healing rates for ranitidine of 92% at 4 weeks and 100l% at 8 weeks compared with a healing rate of 29% for placebotreated patients at 4 weeks (Lee, Costello and Fielding, 1982) . The healing rates for ranitidine are comparable to those reported for cimetidine (Gray et al., 1977; Northfield & Blackwood, 1977; Bardhan et al., 1977) . Clearly, ranitidine is at least as effective as cimetidine in the short-term healing of duodenal ulceration.
Previous reports have shown conflicting results in ulcer healing rates in men and women. reported that women were less likely than men to heal duodenal ulcers after 4 weeks' treatment with H2 receptor antagonists. This trend had become apparent in more recent studies and selection factors may have been relevant. In contrast, no difference was noted between men and women in two studies involving placebo and H2 blockers (Porro et al., 1981) and low-dose antacid (Massarrat and Eisenmann, 1981) although, in this latter study, the trend was in favour of women. A favourable effect for women was found in a trial involving placebo, cimetidine and pirenzipine (Sonnenberg et al., 1981) . At the high (Massarrat and Eisenmann, 1981; Sonnenberg et al., 1981; Korman et al., 1981) . At the healing rates relevant to currently used ulcer healing agents, very large numbers may be needed to detect differences.
Choice of agent, therefore, may depend on other factors such as compliance, unwanted effects and relapse rates after healing. Cimetidine has been shown to affect the hepatic metabolism of a number of drugs including antipyrine and aminopyrine (Staiger et al., 1980; Henry et al., 1980) , warfarin and phenindione (Hetzel, Birkett and Miners, 1979) , chlordiazepoxide and diazepam (Patwardham et al., 1980) , phenytoin (Hetzel et al., 1981) and propranolol (Heagerty et al., 1981) . In addition, cimetidine produces an elevation of serum prolactin levels after intravenous injection (Nelis and Van de Meene, 1980; Kleist et al., 1981) . Ranitidine has been reported as showing more prolonged gastric acid suppression than cimetidine in a man with Zollinger-Ellison syndrome in whom gynaecomastia regressed and sexual activity improved when ranitidine was substituted for cimetidine (Mignon et aL, 1980) . The increased potency of ranitidine has been found useful in patients with life-threatening gastric hypersecretion resistant to cimetidine (Danilewitz, Tim and Hirschowitz, 1982) . Like histamine, cimetidine has an imidazole ring and it may be that some of its unwanted effects are associated with its ring structure. Ranitidine has a nitrofuran ring and is a specific H2 receptor antagonist. Cimetidine has been in use for over 5 years and has an excellent tolerance and safety record. However, there are reservations about anti-androgenic activity and alterations in drug metabolism. These effects do not occur with ranitidine and there may be clinical situations where ranitidine is the preferred agent. 
